Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
July 24, 2019 09:25 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative...
Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
January 07, 2019 08:39 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer
May 16, 2018 08:00 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., May 16, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
April 09, 2018 08:00 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., April 09, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
April 04, 2018 08:00 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., April 04, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute, Inc. Announces Close of Convertible Note Financing
April 03, 2018 13:26 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., April 03, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
December 26, 2017 11:41 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
December 26, 2017 08:00 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
December 07, 2017 08:30 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:ANTB), a clinical stage biopharmaceutical company specializing in the development of...
AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
October 17, 2017 08:00 ET
|
AntriaBio, Inc.
LOUISVILLE, Colo., Oct. 17, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“AntriaBio” or the “Company”) (OTCQB:ANTB), a biopharmaceutical company focused on developing therapies to address significant...